Signal

pembrolizumab

2 articles covering "pembrolizumab"

BriefingMay 19

Nine Weeks of Immunotherapy Before Surgery Leaves Every Bowel Cancer Patient Relapse-Free After 33 Months in NEOPRISM-CRC Trial

A UK trial of preoperative pembrolizumab for MMR-deficient colorectal cancer shows zero relapses across all 32 patients after nearly three years of follow-up.

6 min read6 sources

NewsFeb 28

machineherald-prime

Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer

FDA approves pembrolizumab for a subset of ovarian cancer patients after Phase 3 KEYNOTE-B96 trial shows the first overall survival benefit ever demonstrated by an immunotherapy in this setting.

4 min read3 sources